Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 617 - 624 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC3651 | SB 415286 |
|
Potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor (K<sub>i</sub> = 31 nM for GSK-3<span class='symbol'>α</span>); competes with ATP. Has minimal activity against 24 other protein kinases (IC<sub>50</sub> > 10 <span class='symbol'>μ</span> M). Stimulates glycogen synthesis, gene transcription and is neuroprotective.
|
|
| BCC3652 | Splitomicin |
|
Inhibitor of Sir2p (IC<sub>50</sub> = 60 <span class='symbol'>μ</span>M), an NAD<sup>+</sup>-dependent Sir2 family deacetylase required for chromatin-dependent silencing in yeast.
|
|
| BCC3653 | Cycloheximide |
|
Selective inhibitor of eukaryotic (over prokaryotic) protein synthesis, blocking tRNA binding and release from ribosomes. Induces apoptosis in a variety of transformed and normal cell lines, including T cells. Competitively inhibits the PPIase hFKBP12 (K<sub>i</sub> = 3.4 <span class='symbol'>μ</span>M). Antifungal antibiotic.
|
|
| BCC3658 | SB 431542 |
|
Potent and selective inhibitor of the transforming growth factor-<span class='symbol'>β</span> (TGF-<span class='symbol'>β</span>) type I receptor activin receptor-like kinase ALK5 (IC<sub>50</sub> = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-<span class='symbol'>β</span>-induced proliferation of human osteosarcoma cells. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells. Inhibits TGF-<span class='symbol'>β</span>-induced EMT, migration, invasion and VEGF secretion in several human cancer cell lines.
|
|
| BCC3662 | PD 173074 |
|
Selective FGFR1 and FGFR3 inhibitor (IC50 values are 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively, and > 50000 nM for EGFR, InsR, MEK and PKC). Inhibits VEGF- and FGF-induced angiogenesis in the mouse cornea model of angiogenesis. Inhibits proliferation and differentiation of oligodendrocyte progenitors. Suppresses cell proliferation in cell lines expressing mutated FGFR3 protein. Blocks tumor growth in H510 and H69 SCLC xenograft models.
|
|
| BCC3663 | SB 203580 |
|
Selective inhibitor of p38 MAPK (IC<sub>50</sub> values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38<span class='symbol'>β</span>2 respectively). Displays 100-500-fold selectivity over LCK, GSK-3<span class='symbol'>β</span> and PKB<span class='symbol'>α</span>. Shown to inhibit IL-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase. Enhances clonal growth of skin epithelial progenitor cells; stimulates neural stem cell (NSC) proliferation. Essential component of medium for maintaining stem cells in naive pluripotent state. Part of the MAPK Cascade Inhibitor and MAPK Inhibitor. Water-soluble salt SB 203580 hydrochloride also available.
|
|
| BCC3664 | Sunitinib malate |
|
Potent, ATP-competitive VEGFR, PDGFR<span class='symbol'>β</span> and KIT inhibitor (K<sub>i</sub> values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR<span class='symbol'>β</span> and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
|
|
| BCC3666 | GW788388 |
|
Potent inhibitor of transforming growth factor-<span class='symbol'>β</span> type I receptor (ALK5) (IC<sub>50</sub> values are 18 and 93 nM for ALK5 binding and for TGF-<span class='symbol'>β</span> cellular assay respectively). Inhibits esophageal squamous cell carcinoma (ESCC)-induced neoangiogenesis. Orally active.
|
|